Cypress Bioscience's Prosorba column
This article was originally published in The Gray Sheet
Firm raises $3.3 mil. through a private placement of 2.2 mil. shares of Series A preferred stock to launch the product for expanded use in rheumatoid arthritis. While approved in 1987 for treatment of idiopathic thrombocytopenic purpura, a July PMA for the expanded use is slated to be reviewed by FDA's Gastroenterology and Urology Devices advisory panel on Oct. 29
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.